Extend is a therapeutic platform that transforms academic research into viable biopharmaceutical startups by utilizing gene therapy, cell therapy, and monoclonal antibodies. The company focuses on addressing unmet medical needs in oncology, central nervous system disorders, and rare diseases, facilitating the commercialization of breakthrough scientific discoveries.
Funding
Funding not disclosed
Founders
Product
Problem
Academic research often yields promising therapeutic targets and innovative approaches, but translating these discoveries into viable biopharmaceutical startups faces significant hurdles. The process of validating research in an industrial setting and developing competitive business models requires specialized financial and scientific expertise that is not always readily available. This gap hinders the commercialization of breakthrough science and delays the delivery of new treatments to patients.
Solution
Extend is a biotech hub designed to accelerate the creation of biopharmaceutical startups by bridging the gap between academic research and the market. The company identifies novel therapeutic targets and innovative approaches originating from academic institutions and develops them through an integrated drug discovery process. By combining the necessary financial and scientific skills, Extend validates early-stage research, develops competitive business models, and facilitates the formation of new companies focused on bringing scientific advancements to patients. Extend leverages a tailored path finalized to new start-ups’ creation, we are able to accelerate scientific discovery results and develop competitive business models.
Target Audience
Extend primarily targets academic researchers, universities, and research centers with promising therapeutic targets and innovative approaches in oncology, central nervous system disorders, and rare diseases.
Features
- Identification of novel therapeutic targets and innovative therapeutic approaches from academic research.
- Integrated drug discovery process to develop early-stage research into viable therapeutic candidates.
- Validation of academic research in an industrial setting.
- Development of competitive business models for new biopharmaceutical startups.
- Facilitation of startup creation to bring scientific advancements to patients.